ANVISA forecasts that as many as 4,500 volunteers will participate in the tests: 3,000 in Sao Paulo and 500 in Rio de Janeiro, Bahia and Mato Grosso.
At the end of March, ANVISA denied to import 20 million Covaxin doses into national territory.
In April, Bharat Biotech reported it expanded its manufacturing capacity at various facilities to produce 700 million doses per year.
The Indian pharmaceutical company said it can expand in a short time thanks to the brand-new BSL-3 facilities, the first of its kind for Covaxin vaccine manufacturing in India.
To further increase doses, Bharat Biotech partnered with Indian Immunologicals to manufacture Covaxin´s pharmacological substance.